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Abstract
Background: Medication reviews have become part of pharmacy practice across developed countries. This study
aimed to identify factors affecting the likelihood of eligible Ontario seniors receiving a pharmacy-led medication
review called MedsCheck annual (MCA).
Methods: We designed a cohort study using a random sample of pharmacy claims for MCA-eligible Ontario seniors
using linked administrative data from April 2012 to March 2013. Guided by a conceptual framework, we
constructed a generalized-estimating-equations model to estimate the effect of patient, pharmacy and community
factors on the likelihood of receiving MCA.
Results: Of the 2,878,958 eligible claim-dates, 65,605 included an MCA. Compared to eligible individuals who did
not receive an MCA, recipients were more likely to have a prior MCA (OR = 3.03), receive a new medication on the
claim-date (OR = 1.78), be hypertensive (OR = 1.18) or have a recent hospitalization (OR = 1.07). MCA recipients had
fewer medications (e.g., OR = 0.44 for ≥12 medications versus 0–4 medications), and were less likely to receive an
MCA in a rural (OR = 0.74) or high-volume pharmacy (OR = 0.65).
Conclusions: The most important determinant of receiving an MCA was having had a prior MCA. Overall, MCA
recipients were healthier, younger, urban-dwelling, and taking fewer medications than non-recipients. Policies
regarding current and future medication review programs may need to evolve to ensure that those at greatest
need receive timely and comprehensive medication reviews.
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Background
Inappropriate medication prescribing and use can result in
adverse health outcomes for patients, and increased costs to
healthcare systems [1–3], especially for individuals receiving
multiple medications for multiple conditions. In response,
public drug plans in several countries now reimburse com-
munity pharmacies for one-on-one reviews of patients’ list
of medications [4–7]. Broadly, medication reviews aim to
improve outcomes through educating patients about their
medications and health conditions, promoting safe medica-
tion use, improving adherence, and establishing an effective
patient-pharmacist collaboration [7, 8].
There is no standardized approach to medication reviews.
Across the programs implemented so far, substantial
variation is observed in referral mechanisms, eligibility cri-
teria, pharmacist training, reimbursement schemes, and
frequency, content and location of the reviews [5, 9]. In the
United Kingdom (UK) medication reviews have been classi-
fied into three types: prescription review (a review of pa-
tients’ prescription or medication records); compliance or
concordance review (explores patients’ medication-taking
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practices, knowledge and beliefs); and clinical medication re-
view (conducted with access to patients’ medical record and
with the patient present) [7].
In 2007, the Ontario Ministry of Health and Long-
Term Care (MOHLTC) launched MedsCheck (MC), the
first government-funded, community pharmacy-led
medication review program in Canada [5]. The stated
purpose of the MC service is to help patients better
understand their medication therapy and ensure that
medications are taken as prescribed (MC Program
Guidebook 2008) [10]. Therefore, MC is a compliance
or concordance review. Residents of Ontario taking
three or more prescription medications for a chronic
condition are eligible for a MC. There are no additional
eligibility requirements for the patient, pharmacist, or
community pharmacy. No formal referral is required;
most commonly, community pharmacists approach
patients about receiving a MC. The service must be con-
ducted as a one-on-one interview between patient and
pharmacist in an acoustically private area of the phar-
macy; an appointment is not required. At the time of
this study, the results of the MC had to be shared with
the patient/caregiver in the form of a comprehensive
medication list (prescription and nonprescription drugs
plus natural health products) and, when appropriate,
with the physician. The first service provided through
the MC program was MC Annual (MCA), as described
above, and reimbursed with a fee of $50 (increased to
CAN $60 in 2010). Over time the scope of MC ex-
panded, with MC Follow up, MC Diabetes, MC at Home
and MC Long-term Care (LTC) medication reviews be-
ing introduced at different fee levels.
Since its initiation, the utilization of MCA has in-
creased. Until 2013 about 1.5 million Ontario residents
received MCA at least once [11]. In fiscal year 2012–13
about 327,000 MCAs were provided at an estimated cost
of CAN$22.3 million [11]. However, there has been no
formal evaluation of the program to date. This study
represents one component of a comprehensive evalu-
ation consisting of: i) a description of the characteristics
of patients receiving MCA; ii) factors associated with re-
ceiving MCA; and iii) health outcomes associated with
MCA. In the study reported herein we attempted to
understand the patient, pharmacy and community fac-
tors affecting the likelihood of receiving an MCA among
eligible Ontario seniors.
Methods
We conducted a population-based cohort study of linked
administrative and clinical data to investigate the likelihood
that eligible Ontario seniors would receive an MCA.
Because the Ontario Drug Benefit Program (ODB) provides
prescription drug coverage primarily for Ontario residents
who are over 65 years old, drug claims data were only
available for this population. Therefore, the study population
was limited to Ontario seniors.
The databases used are hosted at Ontario’s Institute for
Clinical Evaluative Sciences (ICES) and include information
for all Ontario residents on: i) demographic and vital statis-
tics (through the Registered Persons Database), ii) comor-
bidities and utilization of inpatient and outpatient healthcare
services (Ontario Health Insurance Plan Physician Claims
database, Discharge Abstract Database and National Ambu-
latory Care Reporting System Database of the Canadian In-
stitute of Health Information), iii) prescription medication
and other Ontario government-funded community phar-
macy services (ODB database). These datasets were linked
using unique encoded identifiers and analyzed at the Insti-
tute for Clinical Evaluative Sciences (ICES). The full data set
creation plan is available from the authors upon request.
We limited the analysis to the period between April 1,
2012 and March 31, 2013 as we expected Ontario com-
munity pharmacies to have adapted their practice to
MCA by then. Also, this represented a period of relative
stability, following a period (2010–2011) in which
reimbursement for a number of new pharmacy-led
medication therapy management (MTM) services were
introduced by the MOHLTC. We excluded claims that
were submitted after the date of death of an individual,
claims for long-term care residents and for MC services
other than MCA. For computational feasibility purposes,
we limited our study to a random 20 % sample of the
seniors identified in the sample period in the ODB data-
base. The sample selection was based on random draws
without replacement from the unique personal identifiers
associated with every eligible senior in the ODB database.
We defined a “claim-date” as any date for which seniors
had a pharmacy claim. These claims could represent dis-
pensing of prescription medication, or providing another
ODB-covered pharmacist service, such as an MCA. We
defined individuals in the ODB as eligible for an MCA on
a given claim-date if they were at least 66 years old (versus
the ODB eligibility date of age 65 to ensure 1 year of look-
back), had claims for three or more chronic prescription
medications over the past 6 months, and had not received
any MC services in the past year. Only eligible ODB claim-
dates during the study period were considered. Finally, we
assumed that MCAs that occurred within 14 days from a
prescription or a pharmacist service claim-date were the re-
sult of an appointment arranged at this claim-date.
As the MC program does not indicate which medications
are considered chronic, or for a chronic condition, we relied
on expert opinion to differentiate between chronic and non-
prescription medications. The list of chronic prescription
medications covered by the ODB program was defined by
two pharmacists who independently reviewed the ODB For-
mulary and excluded drug identification numbers (DINs) of
non-chronic medications. Disagreements were resolved
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through discussion. Over-the-counter and chronic prescrip-
tion medications not covered by the ODB program were
not considered in our patient selection process or analysis.
Conceptual framework and predictor variables
After reviewing relevant policy documents and the pub-
lished literature, we developed a conceptual framework that
summarized potential factors associated with the likelihood
of receiving an MCA (Fig. 1). Factors were classified into
patient-level (age, sex, comorbidities, past experience with
similar services), pharmacy-level (volume), and community-
level (rurality, socio-economic status (SES)). A similar con-
ceptual framework has been used in other healthcare service
studies using Ontario population-level databases [12].
The MC Guidebook lists types of patients most likely to
benefit from an MCA as those with a history of medica-
tion non-compliance, with a significant medication
regimen change, prescribed a high-risk medication, or re-
cently discharged from hospital [10]. Research evidence
supports these characteristics as risk factors for drug-
related morbidity and mortality [13]. Other important fac-
tors are polypharmacy and multiple medical conditions
[1]. Therefore, we included nonadherence (measured
using the proportion of days covered), use of high-risk or
potentially inappropriate medications, number of medica-
tions, and recent hospitalization, as potential predictors of
receiving MCA (see Supplemental Digital Content (SDS)
1, for definitions of these variables). These variables were
defined as patient-level factors.
Patient demographic factors such as age have been
found to have a positive correlation with receiving MTM
services in the US [14] possibly because older adults are
more likely to have multiple medications, chronic condi-
tions and multiple treating physicians. Being a woman
has been associated with a higher probability of receiving
an MTM service [14] which is in accordance with previ-
ous findings indicating that fewer men seek health-
related advice [15]. The literature is conflicting regarding
the effect of the number of medications on the probabil-
ity of receiving a medication review. In a qualitative
study in the UK, pharmacists reported that they were
less likely to provide Medicines Use Reviews (MURs) to
patients who had more medications, complicated medi-
cation regimens or complex conditions because they
perceived these consultations as lengthy [16]. In a survey
of Medicare Part D beneficiaries in the USA, respon-
dents who received a comprehensive medication review
(CMR) as part of their MTM program were prescribed a
significantly higher number of medications than those
who had not [17]. Other patient-level factors included in
our model are comorbidity type; overall level of comor-
bidity, using the Aggregated Diagnosis Groups (ADGs)
metric; number of prescribers; use of high risk and po-
tentially inappropriate medications; and prior experience
with MCA. A diagnosis of dementia was used to repre-
sent patients who would be less likely to receive an
MCA because of inability to visit a pharmacy and/or to
participate in a MCA. Comorbidities were defined using
International Classification of Diseases 10th Revision
(ICD-10) diagnosis codes. The definition of high-risk
medication was based on the list of high-alert medications
in the community proposed by the Institute for Safe
Medication Practices and two recent Canadian reports
[18–20] on adverse drug-related emergency department
visits and hospitalizations.
Pharmacy prescription volume and ownership type
have been identified as pharmacy-level factors influen-
cing provision of medication reviews, with chain phar-
macies being more likely to provide a medication review
[21]. Although our study could not distinguish between
Fig. 1 Conceptual framework of observed and latent predictors for utilization of MCA services MCA, MedsCheck Annual; SES, socio-economic status
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chain and independent pharmacies, we anticipated that
pharmacies with higher ODB prescription volumes
would be more likely to be chain pharmacies.
Community-level factors included socioeconomic status
(SES) and rurality. Lower SES has been associated with
lower uptake of medication reviews [21]. As proxies for SES
we used the neighborhood income quintile and the material
deprivation dimension of the Ontario Marginalization Index
[22]. Rurality was measured by the Rurality Index of Ontario
(RIO), which incorporates information on community popu-
lation density and access to referral centres [23]. Rurality
and SES were based on patients’ enumeration area using
2006 Canada Census data.
Statistical methods
Descriptive statistics were applied to both categorical and
continuous variables. Differences in frequencies were
compared using the χ2 test while mean differences were
compared using an independent t-test. In order to evalu-
ate the independent effects of patient-, pharmacy- and
community-level factors on the likelihood of receiving an
MCA, we used a Generalized Estimating Equations (GEE)
framework to take into account the repeated nature of the
data, since there can be multiple claim-dates for each pa-
tient, and multiple patients within each pharmacy [24, 25].
The variable corresponding to receiving an MCA was
modeled using a binomial distribution. We set the statis-
tical significance level at 0.05 and corrected for type I
error due to multiple testing using the Bonferroni correc-
tion [26]. The quasi-likelihood under the independence
model criterion (QIC) was used to inform the correlation
structure [27]. Model selection was based on the QIC and
our conceptual framework. In order to illustrate our
findings in a more meaningful way we developed four
contrasting scenarios of hypothetical Ontario seniors and




A total of 279,632 seniors in the 20 % random sample
were identified as eligible to receive an MCA between
April 1, 2012 and March 31, 2013, at least once (Fig. 2).
These patients were associated with 2,852,992 eligible
claim-dates and 3,884 pharmacies with unique billing
numbers (almost all unique Ontario pharmacies in
2012–2013). Approximately 23.5 % (n = 65,605) of the
eligible seniors received MCA within the study period.
Table 1 presents descriptive statistics for patient-,
community- and pharmacy-level characteristics of se-
niors with MCA claims compared to those with no
MCA claim on the eligible claim date. Most MCAs were
provided in urban/suburban areas (i.e. RIO < 9) and in
communities with a lower deprivation index. More
MCA recipients were men and younger seniors receiving
fewer medications from fewer prescribers, and with fewer
inappropriate or high risk medications. In addition, phar-
macies with high prescription claims volume were much
less common in the MCA group than in the non-recipient
group.
Predictors of MCA utilization
The final GEE model is presented in Table 2. The model
takes into account the within-patient correlation and as-
sumes a structure of exchangeable correlations across
patients. In accordance with our hypotheses, we found
that having a prior MCA service (OR = 3.03; 95% confi-
dence interval (CI), 2.98–3.09), having a claim for a new
prescription on the eligible claim-date (OR = 1.78; 95%
CI, 1.74–1.81), or using a high risk medication (OR =
1.09; 95% CI, 1.07–1.12) increased the likelihood of re-
ceiving an MCA. Patients with dementia or depression
were less likely to receive an MCA (OR = 0.57; 95% CI,
0.55–0.60 and OR = 0.90; 95% CI, 0.86–0.95 respectively)
while patients with hypertension were more likely (OR =
1.18; 95% CI, 1.15–1.21). However, the likelihood of re-
ceiving an MCA was lower for older patients, patients
with heart failure (HF) (OR = 0.88; 95 % CI, 0.86–0.91),
women (OR = 0.90; 95 % CI, 0.89–0.92), those receiving
either potentially inappropriate medications (OR = 0.90;
95 % CI, 0.88–0.91) or a large number of medications,
those visiting a high-ODB claims volume pharmacy and
those living in a rural community (Table 2). Statistically
significant differences were observed for several other
covariates (e.g. adherence, number of physicians) al-
though their magnitude was not considered clinically
meaningful.
Patient scenarios
Table 3 provides plausible profiles for four hypothetical
seniors, along with their estimated likelihood of receiv-
ing an MCA. Scenario A describes a senior whose char-
acteristics are those of a high risk of MCA senior. The
likelihood of receiving an MCA on an eligible date is
around 11.5 %.In contrast, Scenario D describes a senior
with less favorable profile for MCA. Compared to the
patient in Scenario A, she was estimated to be ten times
less likely (1 %) to receive an MCA on an eligible claim-
date. Scenarios B and C illustrate the likelihood of re-
ceiving an MCA for individuals with other plausible co-
variate combinations.
Discussion
This study aimed at understanding factors affecting the
likelihood of receiving an MCA among Ontario seniors.
Although some groups identified as likely to benefit
from a medication review did receive an MCA (e.g.
those with a prescription for a new medication), the
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profile of seniors receiving MCAs was generally that of
healthier, younger, urban-living seniors on relatively
fewer medications.
Patient factors
Previous MCA experience was the strongest predictor of re-
ceiving an MCA. This finding could be the result of patients’
approaching the pharmacist for another MCA after a posi-
tive prior experience. In a US study 24 % of individuals who
had received a medication review (brown bag review)
responded positively when asked if they would have a review
annually [28]. In addition, from a pharmacist’s perspective,
experienced MCA users may be easy to identify through the
pharmacy’s patient profile system, and engage since they
have responded positively to MCA in the past.
Being on multiple medications or being older had a
strong negative correlation with the likelihood of receiv-
ing an MCA. These findings were contrary to what we
expected based on the Program Guidebook’s list of pa-
tients most likely to benefit from a MC [10] and evi-
dence from an analysis of a US cohort of Medicare
beneficiaries where MTM service enrollees had more
prescriptions than eligible non-MTM enrollees. [17] Re-
garding age, a positive association was observed in a pre-
vious study [14] possibly because the initiation of the
medication review was purely at the discretion of the pa-
tient. It is possible that because MCAs provided to older
seniors with multiple medications are likely to be more
time-consuming and complex, Ontario pharmacists
might show preference in offering the service to younger
and healthier individuals, as has been reported with the
MUR program in the UK [16]. Another explanation
could be that sicker or older patients might not be phys-
ically capable of visiting the pharmacy to pick up their
own prescriptions and thus could not be approached in
person about receiving a MCA.
We postulated that the use of high-risk and potentially
inappropriate medications might be one of the triggers
for initiating MCA. However, we observed that the use
of high-risk medications increased the odds while the
use of potentially inappropriate medications decreased
the odds of receiving an MCA. The characteristics of
users of these two medication groups could differ, with
users of potentially inappropriate medications being
older and more likely to have mental health issues. In
the US MTM program, having a high risk medication
(based on 2002 Beers criteria) increased the likelihood of
enrollment in a medication review program [29].
In our study the average number of ADGs (comorbid-
ity groups) was statistically significant but not clinically
Fig. 2 Flowchart of study sample selection. ODB: Ontario Drug Database, MCA: Medscheck Annual, LTC: long-term care
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Patient-level characteristics defined at the first claim-date
Age (years), n (%)
66–70 16,717 (25.5) 674,825 (24.2) *
71–75 16,444 (25.1) 617,611 (22.2)
76–80 14,754 (22.5) 572,702 (20.6)
81–85 10,741 (16.4) 474,862 (17.0)
86+ 6,949 (10.6) 447,387 (16.0)
Female, n (%) 36,471 (55.6) 1,632,655 (58.6) *
Recent immigrant (<15 years), n (%) 2,086 (3.2) 65,645 (2.4) *
Hypertension, n (%) 55,035 (83.9) 2,286,761 (82.0) *
Ischemic heart disease, n (%) 12,111 (18.5) 534,862 (19.2) *
Heart failure, n (%) 7,281 (11.1) 445,334 (16.0) *
Diabetes, n (%) 17,252 (26.3) 1,054,580 (37.8) *
COPD/asthma, n (%) 20,650 (31.5) 980,904 (35.2) *
Osteoporosis, n (%) 12,875 (19.6) 545,372 (19.6) 0.709
Cancer, n (%) 11,876 (18.1) 500,281 (17.9) 0.311
Depression, n (%) 1,857 (2.8) 110,137 (4.0) *
Dementia, n (%) 2,388 (3.6) 216,747 (7.8) *
Prior MCA, n (%) 37,820 (57.6) 944,962 (33.9) *
Adherent to ACEi/ARB/statin, n (%)
No 4,388 (6.7) 164,301 (5.9) *a
Yes 45,390 (69.2) 1,907,223 (68.4)
NA (not receiving) 15,827 (24.1) 715,863 (25.7)
Number of ADGs in past 2 years, mean (SD) 8.1 (3.7) 8.4 (3.9) *
Number of ED admissions in the last year, mean (SD) 0.6 (1.4) 0.829 (1.8) *
Number of hospitalizations in the last year, mean (SD) 0.5 (0.9) 0.542 (1.1) *
Number of physicians in the last year, mean (SD) 7.9 (6.7) 8.6 (7.8) *
Patient-level characteristics defined at each claim-date
New hospitalization/ED admission in past 60 days, n (%) 9,921 (15.1) 457,454 (16.4) *
Use of high risk medication in past 6 months, n (%) 52,928 (80.7) 2,314,441 (83.0) *
Use of PIMs in past 6 months, n (%) 27,532 (42.0) 1,406,024 (50.4) *
New prescription medication at claim-date, n (%) 16,026 (24.4) 396,030 (14.2) *
Number of physicians in past 3 months, mean (SD) 5.2 (5.0) 5.3 (5.4) *
Number of unique medications in past 4 months, mean (SD) 6.7 (3.5) 7.8 (4.3) *
Number of unique medications in past 4 months (quintiles), n (%)
0–4 19,232 (29.3) 668635 (24.0) *
5–6 17,672 (26.9) 553817 (19.9)
7–8 12,529 (19.1) 507791 (18.2)
9–11 10,111 (15.4) 544720 (19.5)
12–42 6,061 (9.2) 512424 (18.4)
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different between MCA and non-MCA groups. Having
HF, diabetes, depression or dementia, decreased the
odds of receiving an MCA; having hypertension
increased the odds; and having chronic obstructive
pulmonary disease/asthma had no clinically meaningful
effect. In a US study, seniors who used a coupon for a
free medication review were more likely to have high
blood pressure (consistent with our finding), high chol-
esterol, or diabetes (inconsistent with our finding) [14].
Ontario residents with diabetes are eligible for MC Dia-
betes, and that is likely why having diabetes decreased
the probability of getting an MCA. Nevertheless, despite
the availability of MC Diabetes, a considerable number
of individuals with diabetes received an MCA.
We assessed medication adherence, one of the intended
outcomes of MCA [10], for three types of medications
(ACEi, ARBs, statins) that three-fourths of our study
population was receiving. We found that adherence with
these drugs was high in the overall study population,
irrespective of receiving an MCA. This potentially com-
promised our ability to determine whether nonadherence
was a factor in patient selection. A contrasting but also un-
expected finding of an analysis of Medicare beneficiaries
showed that HF or diabetes patients who had better adher-
ence were somewhat more likely to be enrolled into MTM
services, and more likely to have a CMR in particular [29].
The researchers postulated that better adherence was an in-
dicator of a ‘healthy user’ effect, which would also mean that
these patients would be more likely to pursue a health-
seeking behavior such as medication reviews [30].
A hospitalization or ED visit in the last year had little
or no effect on the likelihood of receiving an MCA. A
hospitalization or ED visit within 60 days of the eligible
claim-date, in contrast, increased the odds of getting an
MCA by 7 %. It is possible that such patients also re-
ceived new prescriptions at discharge and visited a phar-
macy to have them dispensed, which triggered the MCA.
Pharmacy factors
In a UK study, pharmacy ownership type was the most sig-
nificant determinant of MUR uptake, with chain pharmacies
more likely to conduct MURs than independent pharmacies
Table 1 Patient, pharmacy and community level characteristics on MCA-eligible pharmacy claim-dates (Continued)
Pharmacy-level characteristic
Pharmacy volume (quintiles), n (%)
1 (lowest) 4,940 (7.8) 137,937 (5.1) *
2 9,147 (14.5) 283,112 (10.5)
3 13,661 (21.6) 461,396 (17.2)
4 16,757 (26.5) 675,308 (25.1)
5 (highest) 18,726 (29.6) 1,129,756 (42.0)
Community-level characteristics
Rurality index of Ontario, n (%)
0–9 (major urban) 47,470 (72.8) 1,744,607 (63.2) *
10–44 (non-major urban) 14,210 (21.8) 803,936 (29.1)
45+ (rural) 3,559 (5.5) 211,667 (7.7)
Income quintiles, n (%)
1 (lowest) 11,582 (17.7) 569,300 (20.5) *
2 13,593 (20.8) 583,981 (21.0)
3 12,999 (19.9) 546,306 (19.7)
4 13,397 (20.5) 542,397 (19.5)
5 (highest) 13,825 (21.1) 533,984 (19.2)
Material deprivation quintiles, n (%)
1 (lowest) 16,114 (24.8) 602,791 (22.0) *
2 15,327 (23.6) 610,747 (22.3)
3 13,919 (21.4) 591,068 (21.5)
4 11,192 (17.2) 515,031 (18.8)
5 (highest) 8,365 (12.9) 424,022 (15.5)
*P-value < 0.001. a‘No’ versus ‘Yes’
ACEi indicates angiotensin converting enzyme inhibitor; ADG Aggregated Diagnosis Group based on the Johns Hopkins Ambulatory Care Group case-mix system,
ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, ED emergency department, MCA MedsCheck Annual, NA not applicable, PIM
Potentially inappropriate medication, SD standard deviation
Pechlivanoglou et al. BMC Health Services Research  (2016) 16:666 Page 7 of 12
Table 2 Results of GEE model analysis to identify patient, pharmacy, and community factors associated with receiving an MCA service
Parameter Odds Ratio 95 % CI P-value
Intercept 0.029 0.028 0.031 *
Age, years (reference: 66–70)
71–75 0.999 0.976 1.022
76–80 0.989 0.966 1.014
81–85 0.922 0.897 0.948 *
86+ 0.716 0.694 0.740 *
Female 0.904 0.888 0.919 *
Recent immigrant <15 years 1.016 0.969 1.066
Hypertension 1.176 1.149 1.205 *
Ischemic heart disease 1.045 1.021 1.070 *
Heart failure 0.884 0.859 0.910 *
Diabetes 0.614 0.601 0.627 *
COPD/asthma 0.978 0.960 0.997
Depression 0.903 0.858 0.951 *
Dementia 0.574 0.548 0.600 *
Prior MCA 3.032 2.979 3.086 *
Adherence to ACEi/ARB/statin (reference: non–adherent)
Adherent to ACEi/ARB/statin 1.043 1.008 1.080
Not receiving ACEi/ARB/statin 0.897 0.865 0.931 *
Number of ADGs in past 2 years 0.994 0.991 0.997 *
Number of ED visits in the last year 0.981 0.972 0.989 *
Number of hospitalizations in the last year 0.990 0.979 1.001
Number of physicians in the last year 0.994 0.992 0.996 *
New hospitalization/ED admission in past 60 days 1.065 1.041 1.090 *
Use of high risk medication in past 6 months 1.091 1.066 1.116 *
Use of PIMs in past 6 months 0.896 0.880 0.912 *
New prescription medication at claim-date 1.776 1.744 1.808 *
Number of physicians in past 3 months 1.013 1.011 1.015 *
No. unique medications in the past 4 months (reference category: 0–4)
5–6 1.010 0.988 1.033
7–8 0.803 0.782 0.824 *
9–11 0.641 0.622 0.660 *
11+ 0.443 0.427 0.460 *
Pharmacy volumea (reference category: lowest)
2 0.884 0.851 0.918 *
3 0.870 0.839 0.901 *
4 0.784 0.757 0.812 *
5 (highest) 0.649 0.626 0.672 *
Rurality index of Ontario (reference category: major urban, 0–9)
10–44 (non-major urban) 0.754 0.739 0.770 *
45+ (rural) 0.737 0.710 0.765 *
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[21]. Because Ontario administrative databases do not cap-
ture pharmacy ownership data, pharmacy claims volume
was the only pharmacy-level characteristic in our study. We
identified that although the majority of MCAs was provided
in high-volume pharmacies, the likelihood of receiving an
MCA decreased with increase in pharmacy volume A likely
explanation for this observation is that the relative increase
on the pharmacist’s dispensing workload due to a MCA in a
higher volume pharmacy is disproportionately high com-
pared to the increase on a lower volume. In other words,
pharmacies dispensing a high volume of prescriptions are
less likely to have slack time that could be devoted to medi-
cation management services such as MedsCheck.
Community factors
Residents of rural or non-major urban areas were
found to have 27 % lower odds of receiving an MCA
on an eligible claim-date compared to those living in
major urban areas. Overall, 73 % of MCAs were
delivered to patients who lived in urban areas as op-
posed to patients from non-major urban and rural
areas. Similarly, in a US study, distance to the nearest
pharmacy was negatively associated with the probabil-
ity of getting a brown bag review where one mile in-
crease in distance decreased the probability by 4 %
[14]. An analysis of the Nova Scotia Seniors Pharma-
care Medication Review program found that 75 % of
pharmacies that provided the service were urban [31].
Consistent with findings in a UK study22 neighbor-
hood income and material deprivation were negatively
associated with receiving an MCA; however, the mag-
nitude of the effect was not meaningful. Further stud-
ies with patient-level SES data would be needed to
establish association with receiving MCA.
Table 2 Results of GEE model analysis to identify patient, pharmacy, and community factors associated with receiving an MCA service
(Continued)
Income quintile (reference category: lowest)
2 1.056 1.028 1.085 *
3 1.051 1.023 1.080 *
4 1.058 1.029 1.087 *
5 (Highest) 1.079 1.050 1.109 *
*P value < Bonferroni corrected α: 0.0012. aQuantiles formed from the number of claims per pharmacy from April 1st 2011 to March 31st 2012
ACEi indicates angiotensin converting enzyme inhibitor, ADG Aggregated Diagnosis Group based on the Johns Hopkins Ambulatory Care Group case-mix system,
ARB angiotensin receptor blocker, CI confidence interval, COPD chronic obstructive pulmonary disease, ED emergency department, MCA MedsCheck Annual, PIM
Potentially inappropriate medication
Table 3 Scenarios of hypothetical seniors, and associated probability of receiving an MCA service on an eligible claim-date
Scenario A Scenario B Scenario C Scenario D
Age (years) 66 80 70 80
New prescription medication at claim-date Yes No Yes No
Number of chronic medications 3 9 5 9
Number of physicians in the last year 1 3 2 3
Number of comorbidities 2 5 3 8
Hypertension Yes Yes Yes No
Heart failure No Yes No Yes
Recent hospitalization (≤60 days) No Yes No Yes
Use of a high risk medication No No No Yes
Use of a potentially inappropriate medication No Yes No Yes
Adherent use of ACEi/ARB/statins Yes Yes Yes Yes
Prior MCA Yes Yes No No
Sex Male Female Male Female
Residence setting Urban Urban Rural Urban
Income level (quintiles) Highest Highest Lowest Highest
Pharmacy volume (quintiles) Highest Highest Lowest Highest
Probability of receiving an MCA service (%) 11.5 4.9 4.7 1.0
ACEi indicates Angiotensin-converting-enzyme inhibitor, ARB Angiotensin II receptor blocker
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Limitations
Although administrative data provide a powerful tool to
answer research questions in a real-world setting they
are also associated with a number of limitations. The
fact that the ODB plan covers predominantly seniors has
prevented us from evaluating the use of MCA in the en-
tire population of MCA recipients. Also, in this study we
had to deviate slightly on the eligibility definition com-
pared to the MC program, as the original definition of
the MC program required a senior to be on three medi-
cations for a chronic condition, while we assumed that
the definition of a MC program required three chronic
prescription medications. In addition, given that the
ODB database captures only information about publicly-
funded medications, prescription medications covered
by private insurance could not be considered. The points
above indicate that a small number of claim-dates could
have been misclassified as ineligible. However, previous
work from our group [11] has identified that most se-
niors who are <65 are on more than three chronic medi-
cations. Furthermore, pharmacists are aware that the
MOHLTC does pharmacy audits for MCAs delivered to
potentially ineligible individuals. Therefore, we expect
that despite the variation on the definition of chronic
medication and the inclusion of only publicly-funded
medications, it is unlikely that an individual is receiving
a MCA when not eligible. Finally, as described earlier,
our database does not include any prescription claims
covered by a private insurance plan. Should there have
been more private pay seniors in the MCA group the es-
timated effect of the number and type of prescription
drugs on receiving an MCA would be biased. However,
there is currently no evidence that MCA recipients are
more likely to be privately insured. However, there is
currently no evidence that MCA recipients truly are
more likely to be privately insured.
We identified and excluded a number of claims submit-
ted after the date of death of an individual. In Ontario, it
is legal for a healthcare provider to submit a claim for
health services after the date of death of the individual. In
addition, the proportion of such claims in our dataset was
so small (<0.1 %) that we are confident that by excluding
them we do not introduce any significant bias. We also
implicitly assumed that on an eligible claim date patients
or their caregivers1 had physically visited the pharmacy
and were therefore “at risk” of receiving an MCA. How-
ever, that might not be the case for patients who chose to
have their medication delivered at home or whose medica-
tions were picked up by a caregiver who did not have the
patient’s consent to participate in an MCA. To minimize
the effect of this assumption on study results, we excluded
residents in long-term care facilities, and included demen-
tia and depression (conditions typically limiting patients
to their home) as covariates in the adjusted analysis.
Nevertheless, there is still a probability that some of the
eligible claim-dates refer to dates where no physical visit
of the patient or eligible caregiver occurred. Future
research should be directed at incorporating additional in-
formation that would help discerning whether a physical
visit indeed would even be possible on an eligible claim-
date. Examples of such information would include mea-
sures of frailty as well as the receipt of home care services.
Similarly, it is impossible to know from the administrative
databases whether the service was requested by the
patient or was initiated by the pharmacist. Therefore, for
those eligible patients who did not receive an MCA, it is
unclear if it was not offered at all or if it was declined by
the patient. We tried to control for the effect of patients’
willingness to receive a MCA by adjusting for medication
adherence, a proxy for a ‘healthy user’ effect [30].
Conclusion
In conclusion, the MCA program appears to have a mixed
record of reaching those seniors most likely to benefit
from a medication review. Seniors prescribed a new or
high-risk medication or those who had been recently
hospitalized were more likely to receive an MCA. In con-
trast, and at odds with our conceptual framework, older
seniors and those with multiple and potentially inappro-
priate medications were less likely to receive an MCA.
Whether this was due to the patient’s physical and/or
mental inability to participate in a medication review in
the pharmacy or to pharmacists’ avoidance of complicated
patients will require additional study. If the barrier to ac-
cess is related to patients’ characteristics, concerted efforts
should be made by policy makers and practitioners to pro-
mote MCAs to caregivers and to recommend MedsCheck
at Home for homebound patients. If the barrier is attribut-
able to pharmacists directing their efforts towards less vul-
nerable eligible recipients, pharmacy and policy makers
may wish to consider strategies to better align program
eligibility criteria with patient need.
Endnotes
1Caregivers are eligible to receive an MCA with signed
consent from the patient [10].
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